{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Staphylococcus+Aureus+Endocarditis", "query": { "condition": "Staphylococcus Aureus Endocarditis" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-22T09:13:42.707Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03138733", "title": "Ceftobiprole in the Treatment of Patients With Staphylococcus Aureus Bacteremia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Staphylococcus Aureus Bacteremia" ], "interventions": [ { "name": "Ceftobiprole medocaril", "type": "DRUG" }, { "name": "Daptomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Basilea Pharmaceutica", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 390, "start_date": "2018-08-26", "completion_date": "2022-03-11", "has_results": true, "last_update_posted_date": "2023-11-08", "last_synced_at": "2026-07-22T09:13:42.707Z", "location_count": 5, "location_summary": "Chula Vista, California • West Palm Beach, Florida • Butte, Montana + 2 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "West Palm Beach", "state": "Florida" }, { "city": "Butte", "state": "Montana" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03138733" }, { "nct_id": "NCT03761953", "title": "Oritavancin for Staphylococcus Aureus Infections in Opioid Users", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Staphylococcus Aureus Bacteremia", "Staphylococcus Aureus Endocarditis" ], "interventions": [ { "name": "Oritavancin Injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-07-01", "completion_date": "2022-03-24", "has_results": false, "last_update_posted_date": "2022-04-06", "last_synced_at": "2026-07-22T09:13:42.707Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03761953" }, { "nct_id": "NCT00638157", "title": "Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Infective Endocarditis" ], "interventions": [ { "name": "daptomycin", "type": "DRUG" }, { "name": "daptomycin and gentamicin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2009-02-13", "completion_date": "2011-11-09", "has_results": true, "last_update_posted_date": "2021-02-02", "last_synced_at": "2026-07-22T09:13:42.707Z", "location_count": 4, "location_summary": "Denver, Colorado • Detroit, Michigan • Philadelphia, Pennsylvania", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00638157" }, { "nct_id": "NCT00695903", "title": "Phase 2 Study of Safety, Efficacy, and Pharmacokinetics of Higher Doses of Daptomycin and Vancomycin in MRSA Bacteremia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Endocarditis, Bacterial", "Infective Endocarditis" ], "interventions": [ { "name": "daptomycin", "type": "DRUG" }, { "name": "vancomycin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 38, "start_date": "2008-09-17", "completion_date": "2010-10-01", "has_results": true, "last_update_posted_date": "2018-12-24", "last_synced_at": "2026-07-22T09:13:42.707Z", "location_count": 2, "location_summary": "Greenville, North Carolina • Cleveland, Ohio", "locations": [ { "city": "Greenville", "state": "North Carolina" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00695903" }, { "nct_id": "NCT03163446", "title": "Safety, Efficacy and Pharmacokinetics of CF-301 vs. Placebo in Addition to Antibacterial Therapy for Treatment of S. Aureus Bacteremia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Staphylococcus Aureus Bacteremia", "Staphylococcus Aureus Endocarditis" ], "interventions": [ { "name": "CF-301", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "ContraFect", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2017-05-23", "completion_date": "2019-03-07", "has_results": true, "last_update_posted_date": "2021-10-08", "last_synced_at": "2026-07-22T09:13:42.707Z", "location_count": 31, "location_summary": "Birmingham, Alabama • Sacramento, California • Sylmar, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Sacramento", "state": "California" }, { "city": "Sylmar", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Newark", "state": "Delaware" } ], "official_url": "https://clinicaltrials.gov/study/NCT03163446" }, { "nct_id": "NCT04597242", "title": "Expanded Access Study of Exebacase in COVID-19 Patients With Persistent MRSA Bacteremia", "overall_status": "NO_LONGER_AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "MRSA Bloodstream Infection", "MRSA Bacteremia", "MRSA Right-sided Endocarditis", "Covid19" ], "interventions": [ { "name": "Exebacase", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ContraFect", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2022-08-31", "last_synced_at": "2026-07-22T09:13:42.707Z", "location_count": 2, "location_summary": "Butte, Montana • Toledo, Ohio", "locations": [ { "city": "Butte", "state": "Montana" }, { "city": "Toledo", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04597242" }, { "nct_id": "NCT05329168", "title": "ERAdicate S. Aureus in Patients With Bacteremia and Endocarditis", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bacteremia Due to Staphylococcus Aureus", "Left Sided Infective Endocarditis (Disorder)", "Right Sided Infective Endocarditis (Disorder)", "Endocarditis Infective" ], "interventions": [ { "name": "Tonabacase (LSVT-1701)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lysovant", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 0, "start_date": "2022-05-01", "completion_date": "2023-11-01", "has_results": false, "last_update_posted_date": "2022-06-30", "last_synced_at": "2026-07-22T09:13:42.707Z", "location_count": 1, "location_summary": "Butte, Montana", "locations": [ { "city": "Butte", "state": "Montana" } ], "official_url": "https://clinicaltrials.gov/study/NCT05329168" }, { "nct_id": "NCT04160468", "title": "Direct Lysis of Staph Aureus Resistant Pathogen Trial of Exebacase", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Staphylococcus Aureus Bacteremia", "Staphylococcus Aureus Endocarditis" ], "interventions": [ { "name": "Exebacase", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "ContraFect", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 259, "start_date": "2019-12-20", "completion_date": "2022-09-09", "has_results": true, "last_update_posted_date": "2023-11-02", "last_synced_at": "2026-07-22T09:13:42.707Z", "location_count": 55, "location_summary": "Birmingham, Alabama • Orange, California • Sacramento, California + 47 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Orange", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Sylmar", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04160468" }, { "nct_id": "NCT01431326", "title": "Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Adenovirus", "Anesthesia", "Anxiety", "Anxiolysis", "Autism", "Autistic Disorder", "Bacterial Meningitis", "Bacterial Septicemia", "Benzodiazepine", "Bipolar Disorder", "Bone and Joint Infections", "Central Nervous System Infections", "Convulsions", "Cytomegalovirus Retinitis", "Early-onset Schizophrenia Spectrum Disorders", "Epilepsy", "General Anesthesia", "Gynecologic Infections", "Herpes Simplex Virus", "Infantile Hemangioma", "Infection", "Inflammation", "Inflammatory Conditions", "Intra-abdominal Infections", "Lower Respiratory Tract Infections", "Migraines", "Pain", "Pneumonia", "Schizophrenia", "Sedation", "Seizures", "Skeletal Muscle Spasms", "Skin and Skin-structure Infections", "Treatment-resistant Schizophrenia", "Urinary Tract Infections", "Withdrawal", "Sepsis", "Gram-negative Infection", "Bradycardia", "Cardiac Arrest", "Cardiac Arrhythmia", "Staphylococcal Infections", "Nosocomial Pneumonia", "Neuromuscular Blockade", "Methicillin Resistant Staphylococcus Aureus", "Endocarditis", "Neutropenia", "Headache", "Fibrinolytic Bleeding", "Pulmonary Arterial Hypertension", "CMV Retinitis", "Hypertension", "Chronic Kidney Diseases", "Hyperaldosteronism", "Hypokalemia", "Heart Failure", "Hemophilia", "Heavy Menstrual Bleeding", "Insomnia" ], "interventions": [ { "name": "The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daniel Benjamin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 3520, "start_date": "2011-11", "completion_date": "2019-11", "has_results": false, "last_update_posted_date": "2023-09-06", "last_synced_at": "2026-07-22T09:13:42.707Z", "location_count": 43, "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01431326" }, { "nct_id": "NCT02208063", "title": "A Phase 3 Telavancin Staphylococcus Aureus (S. Aureus) Bacteremia Trial", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bacteremia" ], "interventions": [ { "name": "Telavancin", "type": "DRUG" }, { "name": "Vancomycin", "type": "DRUG" }, { "name": "Daptomycin", "type": "DRUG" }, { "name": "Synthetic penicillin", "type": "DRUG" }, { "name": "Cefazolin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cumberland Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 121, "start_date": "2014-12", "completion_date": "2018-04-12", "has_results": true, "last_update_posted_date": "2020-02-17", "last_synced_at": "2026-07-22T09:13:42.707Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02208063" } ] }